Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genotype-specific versus pangenotypic regimens in patients infected with hepatitis C virus genotype 1b in real-world settings.

Polish archives of internal medicine - 30 Nov 2021

Pabjan Paweł, Brzdęk Michał, Chrapek Magdalena, Dziedzic Kacper, Stępień Piotr M, Paluch Katarzyna, Garbat Anna, Błoniarczyk Piotr, Reczko Katarzyna, Zarębska-Michaluk Dorota

Abstract excerpt

Introduction: The introduction of direct-acting antivirals (DAAs) has provided us with hope to eliminate hepatitis C virus (HCV) infection as a significant public health problem in the coming years. Objective: Our study aimed to compare the effectiveness and safety of genotype-specific and pangenotypic regimens in genotype 1b–infected patients treated in real-world settings. Patients and methods: Patients were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Hepatitis C

Share to Hepatitis C, Chronic

Share to Liver Cirrhosis

Share to Treatment Outcome

Source

Identifiers

PMID: 34565137
DOI: 10.20452/pamw.16094

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genotype-specific versus pangenotypic regimens in patients infected with hepatitis C virus genotype 1b in real-world settings.PMID 34565137Read ↗

Pangenotypic direct-acting antiviral agents for mixed genotype hepatitis C infection: A real-world effectiveness analysis.Semantic proximity Read ↗

Real-World Efficacy and Safety of Pangenotypic Direct-Acting Antivirals Against Hepatitis C Virus Infection in TaiwanSemantic proximity Read ↗

Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C.Semantic proximity Read ↗

Pan‐genotypic treatment regimens for hepatitis C virus: Advantages and disadvantages in high‐ and low‐income regionsSemantic proximity Read ↗

Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients.Semantic proximity Read ↗

Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era.Semantic proximity Read ↗

Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time.Semantic proximity Read ↗

Efficacy and safety of sofosbuvir-based pangenotypic direct-acting antiviral agents for chronic hepatitis C patients without genotype determination: Real-world experience of a retrospective study.Semantic proximity Read ↗

HCV genotype 4, 5 and 6: Distribution of viral subtypes and sustained virologic response rates in clinical trials of approved direct-acting antiviral regimens.Semantic proximity Read ↗

Effectiveness of pangenotypic retreatment of chronic hepatitis C after prior failure of pangenotypic therapies.Semantic proximity Read ↗

Epidemiological characteristics, genotype patterns, and treatment outcomes in chronic hepatitis C patients receiving direct-acting antivirals: a cohort study from Istanbul, Türkiye.Semantic proximity Read ↗

Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.